Literature DB >> 24599578

A multicenter randomized trial of the effects of exercise dose and type on psychosocial distress in breast cancer patients undergoing chemotherapy.

Kerry S Courneya1, Donald C McKenzie, Karen Gelmon, John R Mackey, Robert D Reid, Yutaka Yasui, Christine M Friedenreich, Cynthia C Forbes, Linda Trinh, Diana Jespersen, Diane Cook, Carolyn Proulx, Evyanne Wooding, Lianne B Dolan, Roanne J Segal.   

Abstract

BACKGROUND: Exercise may improve psychosocial distress in patients with cancer; however, few studies have examined the effects of different types or doses of exercise, or whether exercise effects are related to baseline depression levels.
METHODS: In a multicenter trial in Canada, we randomized 301 patients with breast cancer initiating chemotherapy to thrice weekly, supervised exercise consisting of either a standard dose of 25 to 30 minutes of aerobic exercise (STAN; n = 96), a higher dose of 50 to 60 minutes of aerobic exercise (HIGH; n = 101), or a combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB; n = 104). The primary endpoint was depression assessed by the Center for Epidemiological Studies-Depression scale at baseline, twice during chemotherapy, and postchemotherapy. Secondary endpoints were anxiety, perceived stress, and self-esteem.
RESULTS: Repeated measures ANOVA indicated that neither HIGH [mean difference = -0.9; 95% confidence interval (CI), +0.0 to -1.8; P = 0.061] nor COMB (mean difference = -0.4; 95% CI, +0.5 to -1.3; P = 0.36) was superior to STAN for managing depressive symptoms. In a planned subgroup analysis, there was a significant interaction with baseline depression levels (P interaction = 0.027) indicating that COMB and HIGH were effective for managing depressive symptoms in patients with clinical levels of depressive symptoms at baseline.
CONCLUSIONS: Compared with a standard volume of aerobic exercise, higher volumes of exercise did not help manage depressive symptoms in unselected patients with breast cancer receiving chemotherapy, but they were effective in patients with clinical levels of depressive symptoms at baseline. IMPACT: A phase III exercise trial targeting depressed patients with breast cancer is warranted. ©2014 AACR.

Entities:  

Mesh:

Year:  2014        PMID: 24599578     DOI: 10.1158/1055-9965.EPI-13-1163

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  14 in total

1.  Effects of a multicomponent physical activity behavior change intervention on breast cancer survivor health status outcomes in a randomized controlled trial.

Authors:  Laura Q Rogers; Kerry S Courneya; Stephen J Carter; Philip M Anton; Steven Verhulst; Sandra K Vicari; Randall S Robbs; Edward McAuley
Journal:  Breast Cancer Res Treat       Date:  2016-08-18       Impact factor: 4.872

Review 2.  Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Jessica N Mezzanotte; Michael Grimm; Namrata V Shinde; Timiya Nolan; Lise Worthen-Chaudhari; Nicole O Williams; Maryam B Lustberg
Journal:  Curr Treat Options Oncol       Date:  2022-02-15

3.  A pilot feasibility randomized controlled trial adding behavioral counseling to supervised physical activity in prostate cancer survivors: behavior change in prostate cancer survivors trial (BOOST).

Authors:  Linda Trinh; Arthur F Kramer; Kendrith Rowland; Dominick A Strom; Jaime N Wong; Edward McAuley
Journal:  J Behav Med       Date:  2020-09-26

4.  Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy.

Authors:  K S Courneya; D C McKenzie; J R Mackey; K Gelmon; C M Friedenreich; Y Yasui; R D Reid; J R Vallerand; S C Adams; C Proulx; L B Dolan; E Wooding; R J Segal
Journal:  Br J Cancer       Date:  2014-08-21       Impact factor: 7.640

5.  Predictors of adherence to different types and doses of supervised exercise during breast cancer chemotherapy.

Authors:  Kerry S Courneya; Roanne J Segal; Karen Gelmon; John R Mackey; Christine M Friedenreich; Yutaka Yasui; Robert D Reid; Carolyn Proulx; Linda Trinh; Lianne B Dolan; Evyanne Wooding; James R Vallerand; Donald C McKenzie
Journal:  Int J Behav Nutr Phys Act       Date:  2014-07-06       Impact factor: 6.457

6.  Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study).

Authors:  Marion Kiechle; Christoph Engel; Anika Berling; Katrin Hebestreit; Stephan Bischoff; Ricarda Dukatz; Wolf-Dieter Gerber; Michael Siniatchkin; Katharina Pfeifer; Sabine Grill; Maryam Yahiaoui-Doktor; Ellen Kirsch; Uwe Niederberger; Nicole Marter; Ute Enders; Markus Löffler; Alfons Meindl; Kerstin Rhiem; Rita Schmutzler; Nicole Erickson; Martin Halle
Journal:  Pilot Feasibility Stud       Date:  2016-12-19

7.  Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials.

Authors:  Efrossini D Patsou; Georgios D Alexias; Fotios G Anagnostopoulos; Michalis V Karamouzis
Journal:  ESMO Open       Date:  2017-12-11

Review 8.  Impact of physical exercise in cancer survivors during and after antineoplastic treatments.

Authors:  Martina Ferioli; Giorgio Zauli; Alberto M Martelli; Marco Vitale; James A McCubrey; Simona Ultimo; Silvano Capitani; Luca M Neri
Journal:  Oncotarget       Date:  2018-02-08

9.  Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers - an interventional randomized controlled multicenter trial (LIBRE-1).

Authors:  Marion Kiechle; Ricarda Dukatz; Maryam Yahiaoui-Doktor; Anika Berling; Maryam Basrai; Vera Staiger; Uwe Niederberger; Nicole Marter; Jacqueline Lammert; Sabine Grill; Katharina Pfeifer; Kerstin Rhiem; Rita K Schmutzler; Matthias Laudes; Michael Siniatchkin; Martin Halle; Stephan C Bischoff; Christoph Engel
Journal:  BMC Cancer       Date:  2017-11-10       Impact factor: 4.430

10.  Study design and methods for the Breast Cancer and Exercise Trial in Alberta (BETA).

Authors:  Christine M Friedenreich; Sarah MacLaughlin; Heather K Neilson; Frank Z Stanczyk; Yutaka Yasui; Aalo Duha; Brigid M Lynch; Ciara Kallal; Kerry S Courneya
Journal:  BMC Cancer       Date:  2014-12-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.